These results demonstrate that the inhibition of RIPK1 by Zharp1-163 offers significant protection against TNF-induced SIRS, highlighting Zharp1-163 as a promising RIPK1 inhibitor for the development of potential anti-inflammatory therapeutics. Here, TNF is linked to systemic inflammatory response syndrome.